AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22466349 — intervention group
Group type: COMPARATOR
Intervention: Hypogonadism (after 3 months of Lupron)
Number of subjects: 43
Study 20227097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 30
Study 20227097 — intervention group
Group type: COMPARATOR
Intervention: Retention sutured sequential fascial closure (RSSFC)
Number of subjects: 30
Study 18709009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioplasty using amnion membrane conserved in 76% alcohol
Number of subjects: 60
Study 18709009 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (exposition, occlusive dressing, initial excision with skin grafting)
Number of subjects: 60
Study 15753413 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) 0.4 g/kg body weight, administered at days 0, 1, 2, 30, and 60
Number of subjects: 68
Study 15753413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15753413 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 68
Study 12509314 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 Primary Health Care Guidelines for Diagnosis and Management of Mental Disorders
Number of subjects: 30
Study 12509314 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 10497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone
Number of subjects: 44
Study 10497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (a tranquillizer)
Number of subjects: 44
Study 10497961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9091853 — intervention group
Group type: COMPARATOR
Intervention: Glycogen concentration in neutrophils in diabetics
Number of subjects: 64
Study 9091853 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen contents in neutrophils in IDDM patients
Number of subjects: 64
Study 9091853 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen contents in neutrophils in NIDDM patients
Number of subjects: 64
Study 2003051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilating tube insertion
Number of subjects: 57
Study 2003051 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy alone or no surgery (Control)
Number of subjects: 57
Study 2003051 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 57
Study 6353396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 6353396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6353396 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 0
Study 31711059 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of uric acid
Number of subjects: 989
Study 31711059 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypes of rs11722228
Number of subjects: 989
Study 31752833 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phone application for continuing medical education (CME)
Number of subjects: 107
Study 31752833 — intervention group
Group type: COMPARATOR
Intervention: Booklet, CME seminar, and pamphlet (Control)
Number of subjects: 107
Study 30295338 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase plus fingolimod
Number of subjects: 46
Study 30295338 — intervention group
Group type: COMPARATOR
Intervention: Alteplase alone
Number of subjects: 46
Study 27822028 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 30
Study 27822028 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30
Study 25270861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 160
Study 25270861 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 160
Study 22363556 — intervention group
Group type: EXPERIMENTAL
Intervention: High altitude exposure (3700 m) for 50 days
Number of subjects: 194
Study 22363556 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to low altitude (1500 m) after 50 days
Number of subjects: 194
Study 22363556 — intervention group
Group type: COMPARATOR
Intervention: Control group (low altitude)
Number of subjects: 194
Study 19648220 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 14
Study 19648220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17942389 — intervention group
Group type: EXPERIMENTAL
Intervention: Email notifications about a nutrition education website sent over a period of 4 months (up to 4 messages).
Number of subjects: 755
Study 17942389 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to email notifications.
Number of subjects: 755
Study 17942389 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders to email notifications.
Number of subjects: 755
Study 15962680 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 635
Study 15962680 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tetanus toxoid)
Number of subjects: 635
Study 12541005 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention
Number of subjects: 24
Study 12541005 — intervention group
Group type: COMPARATOR
Intervention: Local services only
Number of subjects: 24
Study 10729668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 36
Study 10729668 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 36
Study 8971505 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation to the mediastinum (50‐56 Gy, 8 or 23 MeV photons, 2 Gy/day, 5 days a week) starting 4 weeks after the operation.
Number of subjects: 155
Study 8971505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further oncologic treatment).
Number of subjects: 155
Study 1309083 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted communication of medical information between the chronic care patient and the physician
Number of subjects: 20
Study 1309083 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 3981628 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management treatment
Number of subjects: 12
Study 3981628 — intervention group
Group type: COMPARATOR
Intervention: Brief consultation program
Number of subjects: 12
Study 30803493 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate (KNO3) mouthrinse plus fluoride toothpaste
Number of subjects: 191
Study 30803493 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste alone
Number of subjects: 191
Study 30033477 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform-based implementation strategy for 12 months
Number of subjects: 473
Study 30033477 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 473
Study 27206648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency sampling (cohorts 1-3)
Number of subjects: 18
Study 27206648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen pretreatment (800 mg) before catheterization (cohort 3)
Number of subjects: 18
Study 27206648 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized low-frequency sampling protocol (cohort 4)
Number of subjects: 18
Study 27206648 — intervention group
Group type: COMPARATOR
Intervention: Control group (cohort 2; sampling started 6 h post catheterization)
Number of subjects: 18
Study 24602579 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated video curriculum on social determinants of health (SDH)
Number of subjects: 100
Study 24602579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video curriculum)
Number of subjects: 100
Study 22126622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education program targeting oral malodor prevention
Number of subjects: 298
Study 22126622 — intervention group
Group type: COMPARATOR
Intervention: Control group (Grade 2 students)
Number of subjects: 298
Study 20123877 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study 20123877 — intervention group
Group type: COMPARATOR
Intervention: Intraoral infraorbital nerve block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 40
Study 17398191 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 17398191 — intervention group
Group type: COMPARATOR
Intervention: Control (no antihypertensive therapy)
Number of subjects: 0
Study 15723895 — intervention group
Group type: EXPERIMENTAL
Intervention: UCL diabetes self-management programme (UCL-DSMP)
Number of subjects: 0
Study 15723895 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12120905 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate once weekly
Number of subjects: 80
Study 12120905 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate twice weekly
Number of subjects: 80
Study 12120905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (once weekly and twice weekly)
Number of subjects: 80
Study 10451039 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 400 mg total daily dose (b.i.d.), increased to 600 and 800 mg if necessary
Number of subjects: 118
Study 10451039 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg total daily dose (o.d.), increased to 20 and 40 mg if necessary
Number of subjects: 118
Study 12879543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg/day
Number of subjects: 0
Study 12879543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg/day
Number of subjects: 0
Study 12879543 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 12879543 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole and Ketoconazole
Number of subjects: 0
Study 2190975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 74
Study 2190975 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 74
Study 30876403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial intervention
Number of subjects: 0
Study 30876403 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderating factors
Number of subjects: 0
Study 28652463 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 503
Study 28652463 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 503
Study 28652463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol
Number of subjects: 503
Study 28652463 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model of insulin resistance
Number of subjects: 503
Study 25872567 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral curcumin at the target dose determined in Phase I
Number of subjects: 33
Study 25872567 — intervention group
Group type: COMPARATOR
Intervention: Standard care oxaliplatin-based chemotherapy alone
Number of subjects: 33
Study 23081732 — intervention group
Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 120
Study 23081732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ff genotype
Number of subjects: 120
Study 23081732 — intervention group
Group type: COMPARATOR
Intervention: Bsm1 genotype
Number of subjects: 120
Study 23081732 — intervention group
Group type: COMPARATOR
Intervention: Fok1 genotype
Number of subjects: 120
Study 21429609 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy (6Fx/week)
Number of subjects: 794
Study 21429609 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionated radiotherapy
Number of subjects: 794
Study 21429609 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 794
Study 19306822 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 308
Study 19306822 — intervention group
Group type: COMPARATOR
Intervention: No gastric bypass (control group)
Number of subjects: 308
Study 19306822 — intervention group
Group type: COMPARATOR
Intervention: Population-based obese individuals (control group)
Number of subjects: 308
Study 16394212 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mediated communication with doctors
Number of subjects: 0
Study 15233827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (N)
Number of subjects: 99
Study 15233827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK)
Number of subjects: 99
Study 11257245 — intervention group
Group type: EXPERIMENTAL
Intervention: eZ.on condom
Number of subjects: 360
Study 11257245 — intervention group
Group type: COMPARATOR
Intervention: latex condom
Number of subjects: 360
Study 9159629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (750 IU per day for 7 to 10 days) and ascorbic acid (1 gm 12 hours before operation)
Number of subjects: 76
Study 9159629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 9159629 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol and ascorbic acid
Number of subjects: 76
Study 8205297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril
Number of subjects: 368
Study 8205297 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Captopril
Number of subjects: 368
Study 8205297 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa + Captopril
Number of subjects: 368
Study 8205297 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 368
Study 8205297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 8205297 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL Assessment
Number of subjects: 368
Study 3581681 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40
Study 3581681 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 40
Study 29952809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 12 weeks
Number of subjects: 30
Study 29952809 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation plus Oral Nutritional Supplement (PRONS) for 12 weeks
Number of subjects: 30
Study 27601237 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg
Number of subjects: 468
Study 27601237 — intervention group
Group type: COMPARATOR
Intervention: Afatinib 40 mg
Number of subjects: 468
Study 27601237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction within the first 6 months
Number of subjects: 468
Study 27601237 — intervention group
Group type: COMPARATOR
Intervention: No dose reduction within the first 6 months
Number of subjects: 468
Study 24709304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 71
Study 24709304 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation
Number of subjects: 71
Study 22497024 — intervention group
Group type: EXPERIMENTAL
Intervention: External stent drainage of the pancreatic duct (stented group)
Number of subjects: 93
Study 22497024 — intervention group
Group type: COMPARATOR
Intervention: No external stent drainage of the pancreatic duct (non-stented group)
Number of subjects: 93
Study 22497024 — intervention group
Group type: EXPERIMENTAL
Intervention: External stent drainage of the pancreatic duct (stented group) among patients with non-dilated duct
Number of subjects: 93
Study 22497024 — intervention group
Group type: COMPARATOR
Intervention: No external stent drainage of the pancreatic duct (non-stented group) among patients with non-dilated duct
Number of subjects: 93
Study 21111098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer eating a large amount of breakfast
Number of subjects: 57
Study 21111098 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer eating a small amount of breakfast
Number of subjects: 57
Study 21111098 — intervention group
Group type: COMPARATOR
Intervention: Peer eating nothing
Number of subjects: 57
Study 21111098 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-Breakfast condition
Number of subjects: 57
Study 18496149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg/kg)
Number of subjects: 90
Study 18496149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (1 mg/kg)
Number of subjects: 90
Study 18496149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16083921 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin) treatment
Number of subjects: 64
Study 16083921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study 12679222 — intervention group
Group type: EXPERIMENTAL
Intervention: S 18886 (10 mg single oral dose)
Number of subjects: 20
Study 12679222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10383501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 41
Study 10383501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 41
Study 10383501 — intervention group
Group type: COMPARATOR
Intervention: H. pylori eradication
Number of subjects: 41
Study 8893888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 8893888 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 1856813 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 23
Study 6137969 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.07 mg/kg
Number of subjects: 0
Study 6137969 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg/kg
Number of subjects: 0
Study 6137969 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg/kg
Number of subjects: 0
Study 6137969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31347931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaction adaptive videogames (Lumosity), 10 games, 15 sessions of 30 minutes each
Number of subjects: 48
Study 31347931 — intervention group
Group type: COMPARATOR
Intervention: Active control group played two nonadaptive simulation-strategy games (SimCity and The Sims), 15 sessions of 30 minutes each
Number of subjects: 48
Study 31347931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 48
Study 30594229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase treatment
Number of subjects: 87
Study 30594229 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 87
Study 30594229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 87
Study 25850440 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated espresso
Number of subjects: 77
Study 25850440 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated espresso
Number of subjects: 77
Study 25850440 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water
Number of subjects: 77
Study 24649935 — intervention group
Group type: EXPERIMENTAL
Intervention: 830 nm low-level laser therapy (LLLT) administered five times per week for 2 weeks (average power 60 mW, peak power 8 W, 10 Hz, 600 sec, and 9.7 J/cm² per fracture site)
Number of subjects: 50
Study 24649935 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received sham laser treatment
Number of subjects: 50
Study 22647618 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary parameters of pyridoxal‐phosphate (PLP)‐dependent tryptophan degradation and the level of 4‐pyridoxic acid
Number of subjects: 0
Study 22647618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of 4‐pyridoxic acid to kynurenine
Number of subjects: 0
Study 22647618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of 3‐hydroxyanthranilic acid to 3‐hydroxykynurenine
Number of subjects: 0
Study 22647618 — intervention group
Group type: EXPERIMENTAL
Intervention: PLP-dependent disturbances of tryptophan metabolism
Number of subjects: 0
Study 20435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 0
Study 20435260 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 17852064 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Using Stuff (SUS) - a brief cognitive behavioural therapy (CBT) intervention, 4 to 6 sessions
Number of subjects: 0
Study 17852064 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 17127477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycaemic-index (LGI) diet
Number of subjects: 10
Study 12206443 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month exercise intervention (goal: at least 10 miles of weekly brisk walking or jogging)
Number of subjects: 342
Study 12206443 — intervention group
Group type: COMPARATOR
Intervention: Baseline exercise motivational readiness stage
Number of subjects: 342
Study 15510439 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-word method
Number of subjects: 48
Study 15510439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subword method
Number of subjects: 48
Study 15510439 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined whole-word and subword method
Number of subjects: 48
Study 7550800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention workwear (new coverall, shirt, trousers, underwear, socks, and boots)
Number of subjects: 10
Study 1657656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5 g/day dietary fibre
Number of subjects: 10
Study 1657656 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 g/day dietary fibre
Number of subjects: 10
Study 1657656 — intervention group
Group type: COMPARATOR
Intervention: fibre‐free diet
Number of subjects: 10
Study 7117309 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa and/or physostigmine treatment
Number of subjects: 45
Study 31928229 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyped group (CYP2C19 genotyping via salivary swab)
Number of subjects: 504
Study 31928229 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (no genotyping)
Number of subjects: 504
Study 31928229 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyped group (CYP2C19 genotyping)
Number of subjects: 504